{
    "nctId": "NCT03941665",
    "briefTitle": "Use of Gelronate Gel vs. Aloevera in Preventing/Minimizing Radiation-induced Dermatitis in Breast Cancer Patients",
    "officialTitle": "Double Blind Study - Use of Gelronate Gel vs. Aloevera in Preventing/Minimizing Radiation-induced Dermatitis in Breast Cancer Patients",
    "overallStatus": "COMPLETED",
    "conditions": "Radiation Dermatitis",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 136,
    "primaryOutcomeMeasure": "Development and degree of any skin reaction",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female patients aged at least 18 years with unilateral breast following lumpectomy +/- chemotherapy\n* Planned to receive 42.4 Gy whole breast irradiation +/- boost to tumor bed.\n* ECOG performance status 0-2.\n* Capable of giving written informed consent.\n* No co-morbidities known to affect radiotherapy reactions.\n* No co-existing acute or chronic skin disease.\n* No evidence of infection or inflammation of breast to be treated.\n* Not receiving chemotherapy during radiotherapy course. Biological therapy (e.g. Herceptin) or hormone therapy will be allowed during the study.\n\nExclusion Criteria:\n\n* Chemotherapy within 4 weeks prior to planned start of radiation or chemotherapy planned during radiation.\n* Prior radiotherapy to the chest wall.\n* Collagen vascular disease.\n* Participation in other clinical study.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}